IGF-1 LR3
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Advanced physique users use LR3 to push past the GH-to-IGF-1 ceiling: bigger pumps, fuller muscles, possible site-biased volumization, and a theoretical hyperplasia signal.
Hypoglycemia is a real risk at doses as low as 40 mcg — always have fast-acting carbohydrates on hand, and never train fasted the morning after an evening dose.
Advanced physique users use LR3 to push past the GH-to-IGF-1 ceiling: bigger pumps, fuller muscles, possible site-biased volumization, and a theoretical hyperplasia signal. The practical read is bullish but bounded — strongest when layered onto an already serious GH/food/training setup, much less convincing as a cheap standalone shortcut.
The near-term risk is glucose: shakiness, dizziness, fatigue, or acute hypoglycemia can show up even around 40 mcg, especially with fasted training. The long-tail risks are different from androgen articles: repeated long IGF-1R exposure raises organ-growth and existing-tumor acceleration concerns, while unregulated product quality can turn a planned cycle into a potency guessing game.
LR3 is attractive because it bypasses the hepatic IGF-1 bottleneck for 20-30 hours instead of asking the liver to make more IGF-1 from GH. That is the whole upside. The catch is that pharmaceutical mecasermin/Increlex is the cleaner comparator, while unregulated LR3 often fails the value test unless the user already has GH, food, training, glucose monitoring, and reliable quality control in place.
Polarized but not random. First-use logs can be dramatic — rapid fullness, pumps, vascularity, sleepiness, and multi-pound early scale movement that is mostly glycogen and water. Repeat-use and bloodwork reports are much less romantic: many users get modest or unmeasurable results from underground LR3, then rank Increlex, GH, or secretagogues above it.
Do not use if you have a personal or family history of cancer or tumors — IGF-1 LR3 does not cause cancer but demonstrably accelerates existing malignancies.
Intro
IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1) is a 83-amino-acid recombinant analog of native IGF-1, engineered with two structural modifications: a glutamic acid to arginine substitution at position 3 (hence 'LR3') and a 13-amino-acid N-terminal extension. These changes serve a single pharmacokinetic purpose — to reduce binding to the six IGF-binding proteins (IGFBP-1 through IGFBP-6) that sequester approximately 98% of circulating native IGF-1. By evading these binding proteins, LR3 operates with a half-life of 20–30 hours versus the 10–12 minute free half-life of native IGF-1, giving it sustained receptor access throughout the day from a single daily injection. IGF-1, the principal downstream mediator of growth hormone, is produced primarily in the liver in response to GH signaling. It acts on the IGF-1 receptor (IGF-1R) via PI3K/Akt and MAPK/ERK pathways to drive cellular growth, differentiation, protein synthesis, and anti-apoptosis. LR3 was designed to deliver this signaling at higher effective concentrations by staying free in circulation rather than being immediately bound and neutralized by IGFBPs. In clinical medicine, recombinant IGF-1 (as mecasermin/Increlex) is approved for treating severe primary IGF-1 deficiency (Laron syndrome and related GH receptor disorders) at doses of 40–120 mcg/kg/day — translating to 2.8–8.4 mg/day for a 70 kg adult. Community bodybuilding use operates at 50–500 mcg/day total, a dose that is 6–170x lower than clinical therapeutic use. This dose gap is central to understanding why blood work rarely shows significant serum IGF-1 elevation from underground LR3 at community doses. WADA classifies LongR3-IGF-I as a prohibited growth-promoting peptide. LC-MS/MS detection is possible via immunopurification-assisted methods at 0.5 ng/mL sensitivity; the N-terminal metabolite (Des1-11)-LongR3-IGF-I persists approximately twice as long as the parent compound, extending the detection window. Increlex (mecasermin) is FDA-approved for pediatric IGF-1 deficiency; IGF-1 LR3 has no approved medical indication.
Observed Effects
The most consistent positive signal is acute fullness: users describe large pumps, vascularity, and a 'vacuum' or 'sucking' feeling in the trained muscle within the first week at roughly 80-100 mcg sessions.
Early weight gain should be read mostly as glycogen and water — one 80 mcg four-times-weekly log reported +10 lb over 3 weeks, including +4 lb in week 1, but the article should not imply that this is pure contractile tissue. Site-biased IM use has some coaching and log support, especially around 50 mcg bilateral injections, but LR3 is still a long-acting systemic IGF-1 analog; DES owns the stronger site-specific claim. Recovery and anti-catabolic framing is biologically plausible through IGF-1 signaling, wound-healing literature, and food-restriction animal data, but healthy-adult LR3 hypertrophy trials do not exist. Treat the human performance evidence as community logs plus adjacent IGF-1 class evidence, not a clean RCT-backed muscle-gain claim.
Field Reports
Positive logs cluster around first exposure: 80 mcg four times weekly for 3 weeks produced a reported +10 lb scale change with +4 lb in week 1; 40 mcg pre-workout produced hypoglycemia followed by unusually strong chest and shoulder fullness; 40 mcg bilateral biceps was paired with rapid sleep onset and next-morning energy; and a 20 mcg subQ plus 40 mcg bilateral IM report described an extreme leg-workout pump. Negative or mixed logs explain why the consensus stays cautious: a post-workout evening dose remained active into fasted morning training and triggered hypoglycemia; 1 mg/day subQ produced fullness but poor value at roughly $70/day; one self-test saw no meaningful serum IGF-1 rise after 1 mg/day for a week; and multi-batch reports repeatedly describe quality as hit-or-miss. The strongest practical read is not 'works' or 'does not work.' It is that first-use response can be striking, repeat response is often muted, and source quality dominates the experience more than the label dose.
Community Consensus
The community posture is bullish but bounded. The bullish side is real: LR3 is treated as one of the few compounds that can plausibly add something beyond standard androgen hypertrophy by pushing IGF-1 signaling directly, especially after GH has already raised the ceiling as far as hepatic conversion allows. The boundary is just as real: it is expensive, source-sensitive, glucose-active, and not proven in healthy-adult bodybuilding trials. The strongest consensus use case is advanced physique work — GH-supported growth phases, lagging-site experiments, or final-stage competitive refinement — not first-cycle muscle gain. The substitute framing matters: LR3 demand exists because pharmaceutical mecasermin/Increlex is scarce and expensive, but Increlex is also the cleaner comparator when users want measurable IGF-1 exposure. Community disappointment usually clusters around unregulated quality and repeat-use dropoff rather than around the basic IGF-1 mechanism being implausible. The hyperplasia claim should stay mechanistic, not overclaimed: satellite-cell activation is biologically coherent and supported by non-bodybuilding evidence, but human LR3-at-community-dose proof is absent. GLP-1 muscle-preservation interest is an emerging adjacent use, but the article does not yet have enough female-identified, obesity-medicine, or non-bodybuilder evidence to treat that as a mature protocol lane.
Risks & Monitoring
Hypoglycemia is the dominant acute risk. IGF-1R overlaps enough with insulin-receptor signaling that even community doses can drive glucose disposal, with one first-time 40 mcg pre-workout report producing symptoms within 30 minutes. The risk is not limited to the injection window: LR3's 20-30 hour half-life means an evening dose can still matter the next morning, especially if the user trains fasted or is already glycogen depleted. Edema, water retention, joint discomfort, and rapid fullness are common practical effects and are mechanistically consistent with IGF-1-driven glycogen storage and cellular hydration. Longer exposure changes the risk category. Repeated or continuous use raises concern for organ hypertrophy across cardiac, renal, visceral, and craniofacial tissues; this is the reason the article favors bounded growth phases instead of year-round use. IGF-1 LR3 should not be framed as cancer-causing, but it can accelerate existing malignancy by feeding a proliferative, anti-apoptotic receptor pathway. Personal or family cancer history, overdue screening, or unexplained symptoms should function as stop gates. Less central but still plausible effects include first-use fatigue, injection-site irritation, lipohypertrophy from repeated site use, and acne that is generally less androgen-like than AAS acne.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Hypoglycemia is the article's most heavily flagged acute risk — documented at doses as low as 40 mcg in first-time users via IGF-1R/insulin-receptor cross-reactivity. The 20-30 hour half-life creates an overnight risk pattern; a glucometer is non-negotiable for anyone running LR3, particularly around fasted morning training following an evening dose.
The article's practicalConsiderations explicitly directs baseline serum IGF-1 testing before starting LR3 as informative for response prediction — naturally elevated baseline (400-600 ng/mL) suggests minimal additional response, while lower baseline (125-200 ng/mL) has the most to gain. Baseline also establishes whether the user is already in a high-IGF-1 state where additional pro-proliferative signaling carries more risk.
The article notes serum testing during LR3 use will not confirm activity at community doses (LR3 doesn't reliably raise serum IGF-1) but provides useful contextual data. A lack of expected elevation paired with poor subjective response is consistent with the article's documented underground-source quality problem and may inform the decision to discontinue rather than escalate dose.
Paired with fasting glucose. The article's mechanism section emphasizes IGF-1R/insulin receptor cross-reactivity — fasting insulin establishes baseline pancreatic burden and identifies users with existing insulin resistance who face compounded hypoglycemia management complexity.
Standard metabolic baseline. Captures glycemic context entering the cycle, particularly relevant given the article's documentation of LR3 driving glucose uptake and the advanced GH+Insulin+LR3 stack pattern requiring active blood glucose management.
The article's stackingConflicts marks personal/family history of cancer as a hard contraindication — IGF-1 LR3 does not initiate malignancy but demonstrably accelerates existing tumors via continuous IGF-1R agonism. Baseline cancer markers screen for any subclinical malignancy before starting; the article's practicalConsiderations explicitly recommends regular cancer marker panels and imaging for users planning extended or repeated cycles.
Repeat before each cycle for users running extended or repeated LR3 protocols, per the article's explicit practicalConsiderations guidance. The 20-30 hour half-life means near-continuous receptor activation — the surveillance interval matters more here than for compounds with short pharmacological windows.
Standard pre-treatment baseline. Hematologic abnormalities are part of the cancer-screening context warranted by IGF-1R-driven proliferative signaling; baseline reference enables earlier detection of unexpected changes during cycles.
Baseline kidney function (eGFR, creatinine) and liver enzymes. The article's adverseEffects flags cumulative organ hypertrophy (heart, kidneys, visceral organs, jaw structures) as not fully reversible — baseline renal markers establish the reference point for catching subclinical kidney enlargement on long-term users.
Mid-cycle re-check at 4 weeks. Captures any drift in renal function indicating kidney hypertrophy progression, particularly relevant for users running closer to year-round protocols against the article's explicit stackingConflicts warning.
The article documents cardiac hypertrophy as part of the cumulative organ-hypertrophy risk profile. For users with multi-year LR3 history or stacking with high-dose GH, periodic echo (annually) screens for cardiac wall thickening that bloodwork alone does not detect. Optional unless symptomatic or with extended high-dose history.
Standard cardiometabolic baseline. The compound's continuous receptor activation profile makes longitudinal lipid trending part of the broader 'is this compound straining your system' picture, particularly for users in the advanced GH+Insulin+LR3 stack.
Baseline for users in the bodybuilding or advanced-stack populations the article describes — testosterone is often co-administered or already elevated in these users. Establishes context for any post-cycle bloodwork interpretation rather than directly tracking LR3 effects.
Confirms hypoglycemic-risk profile resolves with the compound's clearance. The article's 4-week minimum off-period reflects when serum LR3 is below pharmacological threshold — post-cycle glucometer trending verifies the hypoglycemia risk window has closed before considering a re-cycle.
Avoid With
Do not combine IGF-1 LR3 with the following. Sorted highest-severity first.
Why:IGF-1R agonism drives cellular proliferation. IGF-1 LR3 does not initiate malignancy but accelerates existing tumors by providing a continuous proliferative signal. The compound's 20–30 hour half-life means near-continuous IGF-1R activation, unlike IGF-1 DES which limits total exposure. Phase II/III oncology trials targeting IGF-1R blockade confirm the IGF axis's role in tumor biology.
What to do:This is an absolute contraindication, not a caution. IGF-1 LR3 is substantially riskier than IGF-1 DES for users with any cancer history because of the prolonged receptor exposure window.
Why:The 20–30 hour half-life means a post-workout evening injection remains pharmacologically active through the following morning. Fasted training in this state — with no carbohydrates to buffer the insulin-like hypoglycemic effect — has produced acute hypoglycemia requiring compound cessation. The compounding factors are additive: overnight LR3 activity + exercise-induced glucose uptake + fasted state.
What to do:Eat before any morning training session when on LR3, regardless of when the last injection was administered.
Why:Both IGF-1 LR3 and insulin drive glucose uptake and can cause hypoglycemia via overlapping insulin receptor cross-reactivity. The combination increases hypoglycemia risk multiplicatively. Lantis + LR3 is a documented advanced stack, but it requires active blood glucose management and familiarity with each compound's individual response profile.
What to do:Appropriate only for experienced users who have used each compound separately. Not a beginner or intermediate stack combination.
Why:Cumulative IGF-1R activation over prolonged periods drives organ hypertrophy (heart, kidneys, visceral organs). Each additional day of use adds to cumulative risk. This is not an acute effect but a long-term structural change that is not fully reversible.
What to do:Cycle to growing phases only. 4–6 weeks on, minimum 4 weeks off. Do not run year-round regardless of dose.
Why:Cold-chain degradation during shipping (China → remailer → dealer) is invisible — unlike Increlex cloudiness, LR3 degradation cannot be visually confirmed. Degraded LR3 may be partially active, inert, or in some cases produce unexpected effects from degradation products.
What to do:Quality is the dominant practical variable. No visual or smell test confirms LR3 integrity. Blood work cannot confirm activity at community doses (doesn't raise serum IGF-1). The only reliable quality verification is LC-MS testing.
Protocols By Goal
Advanced GH-supported physique protocols often describe 100-200 mcg/day IM for 4-6 weeks layered onto GH, with carbohydrate availability and glucose monitoring treated as central.
Lagging-site experiments sometimes use 50-100 mcg split bilaterally for a few post-workout days, but the evidence is weaker than for DES and the effect is better described as site-biased volumization than proven local growth. Cutting-phase reports use LR3 to maintain fullness when estrogen or calories are low, but hypoglycemia risk rises in a deficit. Injury-recovery use alongside BPC-157 or TB-500 exists in community practice, yet no route- or dose-specific clinical protocol validates that stack.
Dosing Details
Reported community tiers cluster around 50-100 mcg/day as conservative exposure, 100-200 mcg/day as a common working range, and 300-500 mcg/day as high-risk advanced use with materially higher hypoglycemia and organ-growth concern.
Intramuscular use is usually described when site-biased effects are the goal; subcutaneous abdominal use appears for convenience but weakens any local-effect argument. Timing is flexible because of the 20-30 hour half-life, though evening use can leave enough activity to raise hypoglycemia risk during fasted morning training. Typical cycle reports run 3-6 weeks on with a break afterward to limit receptor desensitization and continuous growth-factor exposure. Reconstitution math, syringe-unit conversion, and supply instructions are intentionally omitted here because those are operational handling steps, not reader-facing evidence.
Stacks & Alternatives
The foundational stack. GH at 3–5+ IU/day drives receptor upregulation; LR3 directly saturates IGF-1R beyond the liver's hepatic conversion ceiling. Backeljauw et al. RCT confirmed GH + exogenous IGF-1 coadministration produces additive anabolic effects vs either alone. Community users often drop GH dose from 10–12 IU to 4–6 IU when adding Increlex or LR3, maintaining total anabolic drive while controlling costs and reducing GH-specific side effects. Adding IGF-1 to GH increases hypoglycemia risk vs either agent alone — confirmed in the Backeljauw RCT and in community experience. Carbohydrate management is mandatory for the stack.
The advanced anabolic stack. Lantus (long-acting insulin) doubles IGF-1 levels compared to other insulin types and improves insulin sensitivity, directing both insulin and IGF-1 toward skeletal muscle. Lantus 20–30 IU + GH at 4–6 IU + LR3 at 100–200 mcg is the high-end community protocol. This stack requires active blood glucose management and is documented to require significant experience. Triple risk of hypoglycemia. Not appropriate without extensive prior experience with each compound individually.
Community protocol: 30–90 day LR3 cycle followed by 30 days PEG-MGF. The sequence leverages LR3's satellite cell activation followed by PEG-MGF's satellite cell proliferation and differentiation effects. Dosing of PEG-MGF is identical to LR3 (50–500 mcg range). Simultaneous use is not recommended — the two compounds compete at satellite cell receptors. Sequential use only. LR3 first, PEG-MGF after.
Injury recovery and healing stack. BPC-157 and TB-500 provide angiogenic and connective tissue repair effects; IGF-1 LR3 adds GI mucosal protection and systemic tissue regeneration signaling. Community combination for post-injury or high-volume training blocks. Clinical basis exists for IGF-1's wound healing and GI protection properties. BPC-157 and TB-500 community evidence is largely separate; no head-to-head data on the combination.
Cardarine activates PPAR-delta, increasing MMP9 expression in endothelial cells, which degrades IGFBP-3 — freeing more circulating IGF-1 for receptor activation. In users taking Increlex (which raises IGFBP-3 alongside IGF-1), cardarine may partially offset the binding protein increase and improve net free IGF-1. Community-theorized but not directly tested.
Alternatives
Stack Cost
IGF-1 LR3 is high-tax despite low androgen load: its burden comes from hypoglycemia management, long IGF-1R exposure, cancer/organ-growth screening, source fragility, and glucose-aware stack design.
The article's core risk is IGF-1R/insulin-receptor cross-reactivity, with hypoglycemia documented even at 40 mcg and a 20-30 hour half-life that carries overnight risk into fasted morning training.
The article hard-contraindicates personal or family cancer history because prolonged IGF-1R agonism creates a pro-proliferative environment for existing malignancy.
Recommended monitoring includes glucometer use, baseline IGF-1, metabolic labs, cancer-marker screening, and optional structural monitoring for repeated cycles.
The article repeatedly frames unregulated LR3 quality as hard to verify, with bloodwork unable to confirm activity at community doses and many users not repeating after one vial.
- ·Never dose and then train fasted; keep fast-acting carbohydrates available whenever LR3 is active.
- ·Avoid use with personal/family cancer history or overdue cancer screening.
- ·Do not run continuously year-round; use 4-6 week cycles with at least 4 weeks off as the article describes.
- ·Treat insulin co-use as advanced-only and require independent familiarity with glucose response before combining.
- ·Do not escalate dose to compensate for poor response until product quality and baseline IGF-1 context have been considered.
- ·Home glucometer and fast-carbohydrate plan
- ·Baseline IGF-1, glucose, insulin, HbA1c, CBC, and CMP context
- ·Cancer-screening and family-history gate before repeated use
- ·Cold-chain and product-quality uncertainty management
- ·Cycle-length discipline to limit receptor desensitization and organ-growth exposure
The article is not androgen-suppressive, but it demands glucose literacy, cancer-risk screening, source-quality skepticism, injection handling, and restraint around insulin/GH stacks.
- ·Fasted training is non-negotiable
- ·No access to glucose monitoring or fast carbohydrates
- ·Personal/family cancer history or overdue screening
- ·Trying to combine with insulin before learning LR3 response alone
There is no hormonal PCT, but the 20-30 hour half-life means hypoglycemia vigilance continues after the last dose and repeated cycles raise receptor-desensitization and organ-growth concerns.
- ·Loss of pump/fullness as glycogen and water normalize
- ·Receptor desensitization if off-periods are skipped
- ·Unclear whether non-response reflected biology or degraded/underdosed product
Use a glucometer, eat around dosing, carry fast carbohydrates, and avoid fasted training while LR3 remains active.
Treat these as stop gates; use only after screening context is current and avoid long continuous exposure.
Assume underground quality variance before escalating; prioritize tested supply or discontinue rather than chasing with higher doses.
Use each compound separately first; keep insulin combinations specialist-only with active glucose management.
The article treats this as a hard contraindication because LR3 supplies sustained pro-proliferative IGF-1R signaling.
Hypoglycemia is the most common acute safety issue and is amplified by training, fasting, GH, and insulin.
Growth-factor agonism and glucose effects are incompatible with unsupervised pregnancy or lactation exposure.
The article explicitly frames insulin combinations as advanced due overlapping glucose-disposal effects.
Practical Setup
Fast-acting carbohydrates and glucose awareness are the main practical guardrails around LR3. The most repeated failure pattern is dosing late, then training fasted the next morning while the compound is still active.
Baseline serum IGF-1 can contextualize response, but routine serum IGF-1 does not reliably confirm LR3 activity at community doses. Users planning repeated cycles should treat cancer history, overdue screening, organ-growth concern, and glucose dysregulation as stop-gate issues rather than nuisances. Quality control is a dominant uncertainty: visual inspection and routine bloodwork cannot prove product identity or potency. Pharmaceutical mecasermin/Increlex is the cleaner comparator when available through normal medical channels, but it carries its own clinical-grade glucose and growth-factor monitoring burden.
Mechanism Deep Dive
83 amino acid recombinant protein. Two modifications from native IGF-1: (1) glutamic acid → arginine substitution at position 3 (R3 designation), reducing IGFBP binding affinity; (2) 13-amino-acid N-terminal extension (Long designation), further disrupting the IGFBP binding domain while preserving IGF-1R binding. Molecular weight approximately 9.1 kDa. Three disulfide bridges (from native IGF-1 structure preserved). Native IGF-1 circulates approximately 98% bound to six IGF-binding proteins (IGFBP-1 through IGFBP-6), which bind IGF-1 with affinity equal to or greater than the IGF-1 receptor itself. These proteins act as reservoirs that limit free IGF-1 availability. LR3's structural modifications specifically disrupt the IGFBP-binding domain while preserving IGF-1R binding affinity, resulting in dramatically lower IGFBP binding. This is the compound's entire pharmacokinetic rationale. 20–30 hours versus 10–12 minutes (free native IGF-1) or 17 ±8.8 hours (native IGF-1 bound to carrier proteins). The extended half-life results from IGFBP evasion and reduced enzymatic degradation. This means a single daily injection maintains near-constant IGF-1R activation throughout a 24-hour period. IGF-1R belongs to the receptor tyrosine kinase family, closely related to the insulin receptor. Upon IGF-1 binding, receptor autophosphorylation activates PI3K/Akt (driving protein synthesis, glucose uptake, anti-apoptosis) and MAPK/ERK (driving cell proliferation, differentiation). IGF-1R can also undergo nuclear translocation, a signaling pathway distinct from the insulin receptor. The overlapping binding of IGF-1 with the insulin receptor at higher concentrations explains the hypoglycemic mechanism. Most circulating IGF-1 in healthy adults is produced in the liver in response to GH signaling. This production is genetically limited — a 'hepatic bottleneck' that caps endogenous IGF-1 output regardless of GH dose. At GH doses of 3–5+ IU/day, this bottleneck becomes the limiting factor for further IGF-1 signaling. LR3 bypasses this bottleneck by providing exogenous IGF-1R agonism directly, without requiring liver conversion. GH is the principal driver of hepatic IGF-1 production. Most anabolic effects attributed to GH are mediated downstream by IGF-1. The GH → liver → serum IGF-1 → peripheral tissue pathway has multiple regulatory checkpoints: somatostatin suppression, IGFBP buffering, and hepatic conversion capacity. LR3 circumvents all of these by acting directly on peripheral IGF-1R. IGF-1's role in satellite cell (muscle stem cell) activation is the mechanistic basis for the hyperplasia claim. IGF-1R activation on satellite cells drives proliferation and differentiation, potentially increasing myonuclear number and muscle fiber count over time. This process is distinct from the acute hypertrophy response (fiber volume increase) from androgen receptor agonism. Whether bodybuilding doses of LR3 produce measurable hyperplasia in humans is unproven. IGF-1R is a well-established contributor to tumor biology — its proliferative and anti-apoptotic downstream signaling (PI3K/Akt especially) supports tumor cell survival and growth. Multiple phase II/III clinical trials blocking IGF-1R with monoclonal antibodies (attempting to treat cancer by removing this signal) failed to achieve clinical adoption, partly because IR/IGF-1R cross-reactivity made selective blockade metabolically harmful. The implication for LR3 users: agonizing the same receptor with a long-acting compound creates a continuous pro-proliferative environment that any pre-existing malignancy can exploit.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
LR3 has a half-life of 20-30 hours versus 10-12 minutes for free native IGF-1.
Used to explain prolonged receptor exposure and overnight hypoglycemia risk; exact half-life can vary by assay and model.
Mecasermin/Increlex clinical dosing for severe primary IGF-1 deficiency is 40-120 mcg/kg/day, or 2.8-8.4 mg/day for a 70 kg adult.
The article uses this to scope the large gap between approved IGF-1 therapy and community LR3 dosing.
Community bodybuilding use operates at 50-500 mcg/day total, 6-170x lower than clinical therapeutic use.
This is a community protocol range and does not imply clinical efficacy at those doses.
A 40 mcg pre-workout first-time dose produced hypoglycemia within 30 minutes in a community report.
Single-user signal, but consistent with the article's insulin-receptor cross-reactivity mechanism.
An 80 mcg four-times-weekly post-workout protocol produced 10 lb total gain in 3 weeks, including 4 lb in week 1, in one community log.
The article correctly frames rapid early gain as largely water/glycogen rather than pure muscle accretion.
Bloodwork at 1 mg/day for 1 week did not significantly raise serum IGF-1 in a community self-test.
This supports the article's sourcing caveat and the claim that serum IGF-1 does not reliably confirm LR3 activity at community doses.
Increlex 500 mcg IM raised serum IGF-1 from 192 to 337 ng/mL in one personal test referenced by the evidence packet.
Useful comparator showing why pharmaceutical IGF-1 is treated as more measurable than underground LR3.
A GH plus rhIGF-1 coadministration RCT in short children produced additive height gains versus either agent alone, with more hypoglycemia than GH alone.
The article uses this to support GH + IGF mechanistic additivity while preserving the population gap.
LC-MS/MS detection of LongR3-IGF-I is possible at 0.5 ng/mL sensitivity, with a metabolite persisting roughly twice as long as parent compound.
This scopes detection feasibility, not efficacy or safety in users.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.